Publications

Dual inhibition of ACLY and ACSS2 by EVT0185 reduces steatosis, hepatic stellate cell activation, and fibrosis in mouse models of MASH

 61
Dual inhibition of ACLY and ACSS2 by EVT0185 reduces steatosis, hepatic stellate cell activation, and fibrosis in mouse models of MASH

Tags:

Previous Article

Blood test can to identify cancer in patients with non-specific symptoms

Next Article

New drug candidate reverses metabolic liver disease and fibrosis

Related Posts

Interplay between cancer cell lipotypes and disease states

Interplay between cancer cell lipotypes and disease states

 88

Cryo-EM snapshots of NMDA receptor activation illuminate sequential rearrangements

Cryo-EM snapshots of NMDA receptor activation illuminat...

 61

Chelation-based iron uptake mitigates the effects of prolonged high-temperature stress in cool-season grasses

Chelation-based iron uptake mitigates the effects of pr...

 60